The FDA halted the study for JCAR015 last week following the death of three patients who died after a chemotherapy agent called fludarabine was added to the trial.
The FDA is allowing Juno to continue the trial under a new protocol that does not include fludarabine.
JCAR015 is an experimental T cell therapy that involves extracting a patient’s immune system T cells, altering their DNA to improve their ability to detect and kill cancer cells, and then infuse them back into the patient.
Shares of the Seattle-based drug company jumped 28 percent after the FDA lifted the clinical hold.
More articles on infection control and clinical quality:
Alzheimer’s vaccine could be available soon
Northwell Health wins patient safety awards from the NY hospital association
Patients with more say in treatment have fewer side effects
